Jazz Pharmaceuticals "neutral," target price reduced

08/13/07 - Credit Suisse

NEW YORK, August 13 (newratings.com) - Analyst M Goodman of Credit Suisse maintains his "neutral" rating on Jazz Pharmaceuticals (JAZZ). The target price has been reduced from $17 to $16.

In a research note published on August 10, the analyst mentions that the company has posted its 2Q net losses and top-line in-line with the estimates. Jazz Pharmaceuticals achieved robust sales for the Xyrem drug and higher-than-anticipated Antizol sales in the quarter, the analyst says. The company has discontinued the development of the JZP-2 drug for panic attack, Credit Suisse adds.